Last checked at 22 Sep 2017 12:36
Director Dealings / Market Share Purchase
Oxford, UK - 22 September 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the Group, on Friday 22 September 2017 acquired ordinary shares in the Group as set out below under the market share purchase agreement outlined in the Group's announcement on 15 December 2015.
Under the market share purchase agreement, one-third of Dr Tallarigo's fees as Chairman, after tax, are to be used to purchase shares in Oxford BioMedica PLC on a monthly basis at the prevailing market price.
|
|
|
| Interest after purchase | |
Director / PDMR | Title | Price per share (p) | Number of Ordinary Shares acquired | Number of Ordinary Shares | % of total issued share capital |
Dr Lorenzo Tallarigo | Chairman | 8.9p | 29,685 | 2,082,425 | 0.07% |
The issued share capital of the Group is 3,106,253,317 ordinary 1p shares.
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: John Dawson, Chief Executive Officer Stuart Paynter, Chief Financial Officer |
Tel: +44 (0)1865 783 000 |
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton
|
Tel: +44 (0)20 3709 5700 |
Notes for editors
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people. Further information is available at www.oxfordbiomedica.co.uk.